1/2/2014

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-based Therapeutics

1/9/2014

Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES® Nucleic Acid Delivery Technology

1/14/2014

Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology

1/23/2014 

Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan

2/24/2014

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company’s Promissory Note

2/27/2014

Marina Biotech Continues to Build Worldwide Patent Protection for its SMARTICLES® Nucleic Acid Delivery Technology

3/11/2014

Marina Biotech to use its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases

4/2/2014

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-based Diagnostics and Therapeutics for Rare Diseases

5/6/2014

Marina Biotech Presents Clinical Data Demonstrating Delivery of both Single and Double-Stranded Nucleic Acids to Tumors

Scroll Up